Love Pharma (CSE:LUV) has announced the launch of its online shop, a fully integrated eCommerce platform featuring its proprietary products, BLOOM and Auralief at https://lovepharmashop.com/.
"This proprietary online store will be deployed for LOVE's over-the-counter therapeutics arm, for which the company has six exclusive licenses, as previously announced," Love Pharma COO Joshua Maurice said in a statement.
"During the initial soft-launch phase, we are focused on direct-to-consumer sales, supported by integrated social media and digital marketing campaigns. The second phase of B2B sales will build on the success of our B2C marketing and awareness strategies. We are constantly assessing results to establish the most effective B2B launch using our proprietary e-commerce platform," he added.
READ: Love Pharma makes strategic investment in clinical-stage biotechnology company Starton Therapeutics
Love Pharma said it launched the technology infrastructure and applications to leverage social and digital media campaigns, driving consumers to the individual landing pages for Bloom and Auralief products at https://auraliefstrips.com/ and https://bloomarousal.com/, respectively.
The proprietary eCommerce technology can also be deployed with additional products as the over-the-counter offerings scale in the future, it added.
The Vancouver-based company said it can now generate revenue through the sales of Bloom and Auralief from the online stores but cautioned that there is no guarantee related to revenues.
Starton opportunity
Further to its announcement on September 7, 2022, Love Pharma said while it has made a strategic investment in Starton Therapeutics, it does not have an official relationship or strategic alliance with Starton at the moment. It aims to develop opportunities to work together in the future.
The company's investment in Starton Therapeutics is based primarily upon its interest in innovative drug delivery technology such as transdermal patches, which can reduce side effects, transforming patient outcomes with established, approved medicines allowing for streamlined market entry with long-term IP protections.
"Love Pharma looks forward to building upon its strategic investment in Starton. While there is no promise or guarantee in regard to the outcome of the investment for Love Pharma investors, there is significant opportunity for the company considering the robust catalog of IP and innovation Starton has diligently developed and continues to advance going forward," COO Maurice added.
Improving visibility
Love Pharma also announced that it has entered into agreements with Penny Lane Consultants for marketing, communication, shareholder engagement, market making and social media communications services for a period of four months for a total of US$84,267.25.
The marketing and communication program will include certain investor relations activities and is designed to improve the company's visibility, it added.
Love Pharma was founded in 2020, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. The company holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.
Contact the author at jon.hopkins@proactiveinvestors.com